Skip to main content

Rheumatoid Arthritis

      Mycophenolate isn't great for vaccine immunogenicity, but withholding MMF for one week after both doses of recombinant z

      David Liew drdavidliew

      11 months 2 weeks ago
      Mycophenolate isn't great for vaccine immunogenicity, but withholding MMF for one week after both doses of recombinant zoster vaccine boosts Ab titres ++ in this Brazilian RCT. A week off post-vaccine: definitely worth considering in stable disease #ACR24 ABST0247 @RheumNow https://t.co/lajS5DzRbD
      It's been a wild ride over the last 20 years of RA b/tsDMARDs, and fascinating to see how our prescribing habits have ch

      David Liew drdavidliew

      11 months 2 weeks ago
      It's been a wild ride over the last 20 years of RA b/tsDMARDs, and fascinating to see how our prescribing habits have changed over that time. MarketScan data tell a story of fashion and fame. What will the next 20 years be like? #ACR24 ABST0509 @jeffsparks @RheumNow https://t.co/wCcWgkHrvc
      #ACR24 Ab#0771
      ARID5B - transcription factor controls pathologic inflammatory fibroblast
      ARID5B: RA risk locus on GWAS,

      Eric Dein ericdeinmd

      11 months 2 weeks ago
      #ACR24 Ab#0771 ARID5B - transcription factor controls pathologic inflammatory fibroblast ARID5B: RA risk locus on GWAS, also link to SLE, Graves Binds to histone editors to epigenetically regulate fibroblast state ARID5B deletion incr inflamm response, overexpr decr @RheumNow https://t.co/ebKnX1uTuO
      #0509
      📊 RA DMARD Trends in US (2001-2021)

      🧑‍🤝‍🧑 407,728 DMARD starts in 229,365 patients

      📉 csDMARD

      Caoilfhionn Connolly CaoilfhionnMD

      11 months 2 weeks ago
      #0509 📊 RA DMARD Trends in US (2001-2021) 🧑‍🤝‍🧑 407,728 DMARD starts in 229,365 patients 📉 csDMARD use fell (79.7% → 54.7%) ‼️Methotrexate dropped 29% → 15% 📈 bDMARDs (20.3% →33.1%),tsDMARDs (0.1% → 12.2%) both ⬆️⬆️ 💊Biosimilar uptake low #ACR24 @RheumNow @jeffsparks https://t.co/JepaWj7azY
      The Plants for Joints RA continuation made it to #ACR24!

      whole-food plant-based diet, exercise, sleep/stress Rx
      (added

      David Liew drdavidliew

      11 months 2 weeks ago
      The Plants for Joints RA continuation made it to #ACR24! whole-food plant-based diet, exercise, sleep/stress Rx (added on to usual RA care i.e. DMARDs) Gains made during program were sustained, can't undersell lifestyle as part of the overall picture! #ACR24 ABST0530 @RheumNow https://t.co/XSLIwYitpH https://t.co/RfiTX8Z6ff
      Managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. Our study analyzed Google search trends for rheumatic disease topics, offering a fascinating glimpse into how online search behavior can reveal patient needs and experiences. This approach, known as "infodemiology," tracks real-time Google Trends data to understand symptom- and
      Seronegative RA: sometimes there's an assumption that they'll eventually get a 'real' diagnosis

      at @MayoClinic, 85% of

      David Liew drdavidliew

      11 months 2 weeks ago
      Seronegative RA: sometimes there's an assumption that they'll eventually get a 'real' diagnosis at @MayoClinic, 85% of patients diagnosed with seronegative RA kept their diagnosis at 10 years. Usually, seroneg RA means seroneg RA! #ACR24 @MyasoedovaElena ABST0458 @RheumNow https://t.co/hErZVfs08k
      Real-world data from @k_lauper's Jak-pot study (>9000 RA pt) on how quickly b/tsDMARDs work:
      JAKi, TNFi quicker than

      David Liew drdavidliew

      11 months 2 weeks ago
      Real-world data from @k_lauper's Jak-pot study (>9000 RA pt) on how quickly b/tsDMARDs work: JAKi, TNFi quicker than tocilizumab, abatacept Even though they all get to a similar place eventually, some get there quicker (but worth any safety tradeoffs?) #ACR24 ABST0501 @RheumNow https://t.co/YVpTBMe3gi
      Like we've seen in many parts of the world, RA prescribing in Germany is moving away from JAKi, in response to regulator

      David Liew drdavidliew

      11 months 2 weeks ago
      Like we've seen in many parts of the world, RA prescribing in Germany is moving away from JAKi, in response to regulatory safety warnings. Whether all of this is appropriate or not, we'll have to see... #ACR24 ABST0503 @RheumNow https://t.co/VSqdCz6zc5
      Synovial fibroblast gene expression

      Neutron-4 - plays role in axonal outgrowth, affects pain-sensitive neurons
      May hel

      Eric Dein ericdeinmd

      11 months 2 weeks ago
      Synovial fibroblast gene expression Neutron-4 - plays role in axonal outgrowth, affects pain-sensitive neurons May help explain pain in RA, possible targets Year in Review #ACR24 Bridges @RheumNow https://t.co/kpDVKh0C9O
      Amazing review @NamrataRheum on the important role the rheumatologist can play to improve the care of our older patients

      Patricia Harkins DrTrishHarkins

      11 months 2 weeks ago
      Amazing review @NamrataRheum on the important role the rheumatologist can play to improve the care of our older patients! Don’t forget the 5Ms! 🧠Mind (cog/mood) 💊Medication (PIM) 🏃‍♀️Mobility 👉Multi-complexity 💪🏻Matters most (pt priority) @RheumNow #ACR24 #gerirheum https://t.co/0Iv4TdS8AX
      Unlike traditional imaging techniques, MSUS can be easily used at the point-of-care and offers high-resolution images of joints, tendons, and soft tissues, facilitating the early detection of inflammation and structural damage. On Saturday, November 16th at the ACR Convergence 2024, Dr. Veena Ranganath, Dr. Gurjit Kaeley, and Dr. Catherine Bakewell will present the “Proposed ACR Guidance for Use of Musculoskeletal Ultrasound in Rheumatoid and
      ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
      A recent study by Sparks et al reveals evolving trends in DMARD usage for rheumatoid arthritis over two decades in the United States. This retrospective analysis evaluated 407,728 DMARD initiation episodes among 229,365 unique patients from 2001 to 2021.
      RA pearls from #ACR24 review course:
      1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi.
      2. Multimorbid

      Adela Castro AdelaCastro222

      11 months 2 weeks ago
      RA pearls from #ACR24 review course: 1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi. 2. Multimorbidity=Poor outcomes, High risk for mortality. 3. Can RA be truly prevented or we are delaying the inevitable? https://t.co/111w1Myqrg
      ×